EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 5, 2014, Pages 737-748

  Razis, Evangelia ^a   Pentheroudakis, George ^b   Rigakos, George ^a   Bobos, Mattheos ^c   Kouvatseas, George ^d   Tzaida, Olympia ^e   Makatsoris, Thomas ^f   Papakostas, Pavlos ^g   Bai, Maria ^b   Goussia, Anna ^b   Samantas, Epaminontas ^h   Papamichael, Demetrios ⁱ   Romanidou, Ourania ^c   Efstratiou, Ioannis ^j   Tsolaki, Eleftheria ^c   Psyrri, Amanda ^k   De Roock, Wendy ^l   Bafaloukos, Dimitrios ^m   Klouvas, George ^m   Tejpar, Sabine ⁿ   Kalogeras, Konstantine T ^c,o   Pectasides, Dimitrios ^g   Fountzilas, George ^c   more..

^a HYGEIA HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d Health Data Specialists Ltd   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

^f UNIVERSITY OF PATRAS   (Greece)

^g HIPPOKRATION HOSPITAL   (Greece)

^h AGII ANARGIRI CANCER HOSPITAL   (Greece)

ⁱ Bank of Cyprus Group Oncology Centre   (Cyprus)

^j PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^k NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^l DEPARTMENT OF CARDIOLOGY   (Belgium)

^m METROPOLITAN HOSPITAL   (Greece)

ⁿ UNIVERSITY OF LEUVEN   (Belgium)

^o Hellenic Cooperative Oncology Group   (Greece)

more..

Author keywords

Cetuximab; Colorectal cancer; PIK3CA; PTEN

Indexed keywords

AMPHIREGULIN; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FLUOROPYRIMIDINE; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL EVALUATION; DOUBLE BLIND PROCEDURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84901633656     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1626-2     Document Type: Article

References (35)

1. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663-671 Epub 2008 Dec 29
2. Carpenter G, Cohen S (1990) Epidermal growth factor. J Biol Clin 265:7709-7712 (Pubitemid 20158927)
3. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810 (Pubitemid 46211358)
4. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345 (Pubitemid 38944402)
5. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8):753-762. doi:10.1016/S1470-2045(10)70130-3
6. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705-5712
7. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in meta-static colorectal cancer patients. Br J Cancer 97:1139-1145 (Pubitemid 47587019)
8. Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A, Benchimol D, Gugenheim J, Michiels JF (2005) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 16:1503-1507 (Pubitemid 41222423)
9. Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcberg JR, Simes J, Moore MJ, Tebbutt N C, Price T J, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IAJ, for the NCIC Clinical Trials Group and the Australasian Gastro-Intestinal Trials Group (2013) PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the Treatment of Advanced Colorectal Cancer - Results from NCIC CTG/AG ITG CO.17. Published doi:10.1158/1078-0432.CCR-13-0606
10. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ (2007) Expression of epiregulin and amphiregulin and KRAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237 (Pubitemid 47325606)
11. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844-847 (Pubitemid 28331029)
12. Lenz HJ, Van-Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pipas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines. J Clin Oncol 24:4914-4921 (Pubitemid 46630920)
13. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, CôtéJF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2005) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995
14. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer 71:2454-2460 (Pubitemid 23100476)
15. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235 (Pubitemid 44631925)
16. Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Borger E, Teerenstra S, Kamping E, Verwiel E, Koopman M, Meijer GA, van Krieken HJ, Kuiper R, Punt CJ, Nagtegaal ID, van Vliet S (2012) Beyond KRAS mutation status: influence of KRAS copy number status and microRNA s on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 12(1):292
17. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number of epidermal growth factor receptor (EGFR) and clinical response to anti EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-286 (Pubitemid 40590264)
18. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 195:281-289
19. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G (2013) Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13:49. doi:10.1186/1471-2407-13-49
20. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253-1260 (Pubitemid 29488932)
21. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20:84-90
22. Razis E, Briasoulis E, Vrettou E, Skarlos DV, Papamichael D, Kostopoulos I, Samantas E, Xanthakis I, Bobos M, Galanidi E, Bai M, Gikonti I, Koukouma A, Kafiri G, Papakostas P, Kalogeras KT, Kosmidis P, Fountzilas G (2008) Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study. BMC Cancer 8:234. doi:10.1186/1471-2407-8-234
23. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128(2):447-456. doi:10.1007/s10549-011-1572-5
24. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D (2013) A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19(5):619-625. doi:10.1038/nm.3175
25. Saltz LB, Kies M, Abbruzzesse JL, Azarnia N, Needle M (2003) The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignances. Proc Am Soc Clin Oncol 22(204):A817
26. Saltz LB, Meropol NT, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 22:1201-1208 (Pubitemid 41079832)
27. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J (2011) Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients. PLoS ONE 6(1):e15980. doi:10.1371/journal.pone.0015980
28. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851-1857. doi:10.1158/0008-5472
29. Shen Y, Yang J, Xu Z, Gu DY, Chen JF (2012) Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: a meta-analysis. World J Gastroenterol 18(21):2712-2718
30. Skacel M, Skilton B, Pettay JD, Tubbs RR (2002) Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol 10(1):1-6 (Pubitemid 34178269)
31. Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, Franklin W, Said S, Varella-Garcia M (2005) Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 131:111-119 (Pubitemid 40192936)
32. Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536-3544
33. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408-1417
34. Wang ZH, Gao QY, Fang JY (2012) Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. Cancer Chemother Pharmacol 69(6):1647-1655
35. Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh TD, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. N Engl J Med 351(4):337-345